Amarantus Therapeutics Announces Appointment of Lawrence M. Schwartz, Ph.D., to Scientific Advisory Board

SUNNYVALE, CA--(Marketwire - June 16, 2010) - Amarantus Therapeutics, Inc., a privately-held biotechnology company developing first-in-class disease-modifying treatments that address an underlying cause of cell death known as apoptosis, announced the appointment of Lawrence M. Schwartz, Ph.D., to its Scientific Advisory Board.

Dr. Schwartz is currently the Director of the Center of Excellence in Apoptosis Research ('CEAR'), Founding Director of the Pioneer Valley Life Sciences Institute ('PVLSI') in Springfield, Mass., and Professor of Biology at the University of Massachusetts Amherst.

Amarantus is working with Dr. Schwartz and other Massachusetts-based collaborators on the development of its lead protein, AMRS001, for therapeutic applications including Diabetes and Amyotrophic Lateral Sclerosis (ALS), as well as the advancement of scientific research into AMRS001's broad spectrum of apoptosis-prevention potential.

Driven by the Commonwealth of Massachusetts' demonstrated commitment to attracting and supporting the life sciences along with the proximity to world-renowned researchers such as Dr. Schwartz and academic centers of excellence based in the state, the Company is currently engaged in an effort to place a subsidiary, named Amarantus MA, in the Bay State. Expanding Amarantus' operations to include a separate entity will allow the Company to move quickly from research to therapy, as researchers continue to work on the development of AMRS001 to treat a range of life-threatening conditions.

"We are excited to be working with Dr. Schwartz, who is well-known as a scientific expert in the field of apoptosis-based research and development, and also as a life science entrepreneur." said Martin D. Cleary, Chief Executive Officer. "We will continue our pursuit of AMRS001 for Parkinson's disease, cardiac ischemia, and organ transplantation. With guidance from Dr. Schwartz and the other members of our Scientific Team, Amarantus MA intends to expand our efforts to include Diabetes and ALS."

"I am pleased to join the Amarantus team to advance the development of AMRS001 as a potential breakthrough technology in treating a critical biological pathway involved in so many diseases," said Dr. Schwartz. "I am looking forward to building upon the momentum of the scientific and product development interest in AMRS001 and identifying potential new areas of research where AMRS001 could lead to a number of new therapies for the treatment of numerous devastating human disorders."

About Amarantus Therapeutics, Inc.
Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company's most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute, Amarantus Therapeutics is a recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research. The Company is currently fund raising to advance its lead programs into clinical development. www.amarantustherapeutics.com